Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase

Neurodevelopmental Effects of Antiseizure Medications (NEAM) - UG3 Phase

To compare in-person to remote video assessments in children to determine the reliability of remote evaluations for future neuropsychological assessments and set a precedent for future investigations.

Inclusion Criteria:

1. Parents able to provide informed consent for themselves and their child
2. Access to computer and reliable internet connection for remote testing
3. Child of women with epilepsy who was taking antiseizure medications during the pregnancy of the child being enrolled into the current study
4. Child between the ages of 24 months and 30 months of age
5. Primary language is English

Exclusion Criteria:

1. Child unable to complete the cognitive assessment (e.g., expected IQ<70)
2. Child with a major medical condition (e.g., epilepsy, diabetes, heart disease, active cancer)
3. Child who use centrally active medications